All News
Another study suggests poorer outcomes in Rheum pts on Rituximab. French Cohort study of 1090 inflammatory rheumatic MSK pts -13% w/ severe COVID-19 & 8% who died. 63 RTX pts had more severe disease, longer hosp stays & more death (21% vs 7%) https://t.co/5UCvFeVWRS
Links:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)
Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.
Read Article
Comparison of oral and parenteral MTX shows oral MTX in RA is non inferior to subcutaneous MTX treatment (in 640 RA pts) with regard to disease activity, but oral MTX had fewer adverse events than SC ( 41% vs 52%, p= 0.005). https://t.co/828kcG53iz
Links:
Dr. John Cush RheumNow ( View Tweet)
Matched cohort Nurses’ Health Study looked at 283 pre‐RA pts (mean 9.7 years before RA Dx) and and 842 controls; 21% pre‐RA were ACPA+. ACPA+ was associated with increased risk of COPD (HR 3.04) that was not seen in ACPA- pts. https://t.co/HNB11eAiva
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Olga Petryna ( @drpetryna) weighing the future Rx in RA by Dr. Fleischmann:
-CD22, new IL6i & GM-CSF show promises but far form being available
-bDMARD or tsDMARD after MTX but work better wMTX
-JAKS better choice for mono-therapy but safety is a concern
#RNL2021
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from @doctorRBC
ACR’s conditional recommendations for tx of specific RA populations #RheumNow https://t.co/3uo9x42bPX
Dr. John Cush RheumNow ( View Tweet)
263 RA patients with ILD were treated w/ Abatacept (ABA mono, ABA+MTX or ABA+nonMTX) - all improved their DAS28, stablized their FVC, DLCO, CHest CT; Only difference was that steroid sparing best when ABA used in combo. https://t.co/11vJCWOdSG https://t.co/yMF6imuFMV
Links:
Dr. John Cush RheumNow ( View Tweet)
Inflammatory Conditions Up the Risk of Premature Myocardial Infarction
The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.
Read Article
From Dr. Petryna ( @DrPetryna ) on Pneumonia & RA #RNL2021 :
-PNA most common hospital inf in RA and main cause of hosp mortality
-seropositivity assoc w/increase risk of PNA
-COPD+RA bad combo: increase PNA & mortality
#RheumNow https://t.co/IgXfJTMrcn
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 32 studies shows most forms of arthritis assoc w/ incr risk of CVA (ischemic stroke: RR=1.53 or hemorrhagic stroke: RR=1.45), esp for RA (RR=1.38), AS (RR=1.49), PsA (RR=1.33), gout (RR=1.4) --risk higher with age <45 years (RR=1.46) https://t.co/YDiebrqtbi
Links:
Dr. John Cush RheumNow ( View Tweet)
From @KDAO2011 for #RNL2021
Is it better to taper the steroids or leave it?
SEMIRA study. Tapering off low dose steroids cause more flares and more treatment side effects.
Dr. Buttgereit says keep your low dose steroids (prednisone 5 mg/day or less)
https://t.co/FpQnxUKWwF
Links:
Dr. John Cush RheumNow ( View Tweet)
A prevention trial shows atorvastatin failed to prevent RA onset - 62 pts with preclinical RA (arthralgia, +CCP/RF) randomized to PBO or statin. After 14 mos, arthritis developed in 29% with atorvastatin and 19% with placebo. https://t.co/HikuDkwNu7 https://t.co/QyGy81lgcq
Links:
Dr. John Cush RheumNow ( View Tweet)
Liver Management in RA - #RNL2021 Highlight by @DrPetryna
While RA is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the mgmt of many RA patients.
https://t.co/OeuloDIXMF
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned
https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D
Links:
Dr. John Cush RheumNow ( View Tweet)
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Fleischmann vs. Dr. Matsumoto: get rid of MTX vs. get rid of biologic in RA remission. Both argue on sustained remission, risk for anti-drug antibodies, longterm safety. Dr. Buch’s perfect answer… “it depends on patient’s preference, cost.” #RNL2021 https://t.co/FBf2uoDx0B
k dao KDAO2011 ( View Tweet)
Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights
In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning.
Read Article
Adding RTX to leflunomide works but may at ACR50 level. 140 RA pts on LEF given RTX or PBO w/ ongoing LEF. Wk 16, RTX+LEF ACR50=32% (vs PBO 15%; P=0.02), but not wk 24 (27 vs 15%), yet ACR20 was signif. RTX had more SAEs (20 vs 2%) https://t.co/t6Z9m7P2Ur
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: Liver Management in Rheumatoid Arthritis - #RNL2021 Highlight by Dr. Olga Petryna ( @DrPetryna )
https://t.co/OeuloE0yEd https://t.co/qYd1K0dADu
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Buch discusses the differences between difficult to treat vs refractory RA in #RNL2021. @RheumNow https://t.co/TqrHcBt0la
Dr. Rachel Tate uptoTate ( View Tweet)